The report notes Torrent Pharma's consolidated net profit fell 9.6% YoY to ₹534 crore for the September quarter.
Read this note →Torrent Pharmaceuticals Limited
NSE TORNTPHARM BSE 500420 INE685A01028
0 filings · 0 analysed
4,780.00
+2.64%
over 1 month
-
Daily Market Mirror 2026 10 26
The report notes Torrent Pharma's consolidated net profit fell 9.6% YoY to ₹534 crore for the September quarter.
-
The report states quarterly revenue grew 50.8% YoY and operating profit rose 53.8% YoY, though net profit declined 9.6% YoY, described as in line with expectations.
-
HSIE Results Daily 24 Oct 26 HSIE
The report says Torrent Pharma delivered 54% YoY EBITDA growth and 51% YoY sales growth aided by JB Chemicals integration, with TP revised to INR 5,000.
Prices from Yahoo Finance, NSE close, delayed — indicative only, not for dealing. Solid markers sit on the exchange's own timestamp.
Targets, and what happened next
What each house published, and where the price has gone since. Orivam issues no calls of its own and takes no view on these.
| House | Published | Call | Entry | Target | Now | Progress | Standing |
|---|---|---|---|---|---|---|---|
| HDFC Securities | 24 Oct 2026, 06:29 | long | 4,524.40 | 5,000.00 | 4,750.00 | 47% | open by 2027-10-24 |
| HDFC Securities | 07 Oct 2026, 15:25 | long | 4,716.20 | 5,270.00 | 4,750.00 | 6% | open by 2027-10-07 |
Deadlines: 0 stated by the house, the rest set by Orivam’s convention — ten trading days for a technical call, twelve months for a price target. A target with no date cannot be judged, so one has to be chosen.
What the desks said
The report states quarterly revenue grew 50.8% YoY and operating profit rose 53.8% YoY, though net profit declined 9.6% YoY, described as in line with expectations.
Read this note →The report says Torrent Pharma delivered 54% YoY EBITDA growth and 51% YoY sales growth aided by JB Chemicals integration, with TP revised to INR 5,000.
Read this note →The report notes 51% YoY revenue growth (not comparable due to JB Chemicals integration), with margin improvement from cost synergies but flattish PAT growth.
Read this note →The report notes Torrent's EBITDA growth of 47.1% YoY benefiting from JB Pharma consolidation, though PAT is expected to decline 9.3% YoY.
Read this note →The report lists Torrent Pharma as a stock to watch likely to show relative strength given Pharma's strong technical structure.
Read this note →Announcement timeline
No filings stored for this company yet.
Never miss the next one.
Orivam emails what the research desks published each trading morning, attributed and linked to the original notes. Free.
Get the daily brief